Pantop%25252525252525252525252525252520ds

# Pantoprazole (Protonix) ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the $H^+/K^+$-ATPase enzyme system at the secretory surface of the gastric parietal cell. It is available in delayed-release oral tablets and intravenous (IV) formulations. ## Primary Indications * Erosive esophagitis associated with GERD. * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions, including Zollinger-Ellison syndrome. * Short-term treatment of GERD symptoms (off-label). * Stress ulcer prophylaxis in critically ill patients (off-label). ## Adult Dosing * **Erosive Esophagitis:** 40 mg PO or IV once daily for up to 8 weeks. * **Maintenance of Healing:** 40 mg PO once daily. * **Hypersecretory Conditions:** Starting dose 40 mg PO BID. Titrate dose based on patient needs (up to 240 mg/day). Doses >80 mg/day should be divided. * **Stress Ulcer Prophylaxis (Off-label):** 40 mg IV daily. ## Pediatric Dosing * **GERD/Erosive Esophagitis (5 years and older):** * 15 kg to <40 kg: 20 mg PO once daily for up to 8 weeks. * ≥40 kg: 40 mg PO once daily for up to 8 weeks. * **Note:** IV dosing for pediatrics is not standard and should be guided by specific institutional protocols or pediatric specialty guidelines. ## Dose Adjustments * **Hepatic Impairment:** No specific adjustment required for mild to moderate impairment, but consider reducing frequency in severe impairment (dosage guidelines vary by institution; monitor closely). * **Renal Impairment:** No dosage adjustment necessary. * **Geriatric:** No dosage adjustment necessary. ## Contraindications * Known hypersensitivity to pantoprazole or any component of the formulation. * Concurrent use with rilpivirine-containing products. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain. * **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, cutaneous/systemic lupus erythematosus, and increased risk of bone fractures. ## Key Drug Interactions * **PH-Dependent Absorption:** May decrease absorption of drugs like atazanavir, nelfinavir, ketoconazole, and mycophenolate mofetil. * **Methotrexate:** Potential for increased serum levels and toxicity, especially in high-dose therapy. * **Warfarin:** Monitor INR closely; some PPIs may increase INR. ## Monitoring * Monitor for signs of hypomagnesemia (e.g., tremors, arrhythmias) during long-term therapy. * Monitor for *C. difficile* if severe, persistent diarrhea occurs. * Assess for symptom relief and clinical need for ongoing therapy; avoid long-term use unless medically necessary. ## Clinical Pearls * **Administration:** Tablets should be swallowed whole; do not crush or chew. May be administered with or without food. * **IV Administration:** IV pantoprazole should be administered as a slow injection (over at least 2 minutes) or a continuous infusion. * **Tapering:** Long-term users may experience rebound hypersecretion upon abrupt discontinuation; consider a gradual taper or transition to H2-blockers if appropriate. *** **Disclaimer:** This information is for educational purposes only. Always consult current institutional protocols and the manufacturer’s package insert or official prescribing information before prescribing or administering any medication.